Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects, PMID: 20214444
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience, PMID: 28983798
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Treatment Update of Autoimmune Blistering Diseases, PMID: 30850044
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris, PMID: 25133328
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody, PMID: 18941114
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study, PMID: 23829485
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma, PMID: 21173095
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results, PMID: 19451441
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia, PMID: 27515248
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia, PMID: 26389849
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, PMID: 19223402
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, PMID: 25847298
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma, PMID: 25150258
Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura, PMID: 19330725
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab), PMID: 18829494
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line, PMID: 24386925
Rituximab resistance, PMID: 21658619
Bullous Diseases, PMID: 29131038
Future therapies for pemphigus vulgaris: Rituximab and beyond, PMID: 26792592
Novel agents for chronic lymphocytic leukemia, PMID: 23680477
Emerging immunological drugs for chronic lymphocytic leukemia, PMID: 26153226
B-cell depletion in immune thrombocytopenia, PMID: 23664523
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies, PMID: 21090841
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas, PMID: 19710501
Novel CD20 monoclonal antibodies for lymphoma therapy, PMID: 23057966
Shifting Focus in the Therapeutics of Immunobullous Disease, PMID: 28584371
CD20-targeted therapy: the next generation of antibodies, PMID: 20350667
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias, PMID: 20628151
[Novel B-cell directed strategies for the treatment of rheumatic diseases], PMID: 19513729
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era, PMID: 28499646
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment, PMID: 29143151
Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development, PMID: 21105187
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art, PMID: 25249370
The future of CD20 monoclonal antibody therapy in B-cell malignancies, PMID: 20367564
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus, PMID: 24841238
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma, PMID: 20425465
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies, PMID: 22039078
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics, PMID: 18922911
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties, PMID: 23116517
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas, PMID: 22271448
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action, PMID: 18025153
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma, PMID: 19372261
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides, PMID: 20127947
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia, PMID: 19562616
Hepatocyte paraffin 1 immunoexpression in esophageal brush samples, PMID: 15918175
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells, PMID: 20876805
Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody, PMID: 15815716
Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus, PMID: 20534646
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells, PMID: 23696859
Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits., PMID:39339212
Immunotherapy in indolent Non-Hodgkin's Lymphoma., PMID:35663281
Epitope Mapping of Rituximab Using HisMAP Method., PMID:35225667
Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders., PMID:35185862
Complicated Diagnosis and Treatment of HA20 due to Contiguous Gene Deletions involving 6q23.3., PMID:34032947
Treatment Update of Autoimmune Blistering Diseases., PMID:30850044
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment., PMID:29143151
Bullous Diseases., PMID:29131038
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience., PMID:28983798
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID:28765121
Shifting Focus in the Therapeutics of Immunobullous Disease., PMID:28584371
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era., PMID:28499646
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia., PMID:27515248
Future therapies for pemphigus vulgaris: Rituximab and beyond., PMID:26792592
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia., PMID:26389849
Emerging immunological drugs for chronic lymphocytic leukemia., PMID:26153226
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma., PMID:25847298
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art., PMID:25249370
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma., PMID:25150258
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris., PMID:25133328
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus., PMID:24841238
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line., PMID:24386925
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study., PMID:23829485
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells., PMID:23696859
Novel agents for chronic lymphocytic leukemia., PMID:23680477
B-cell depletion in immune thrombocytopenia., PMID:23664523
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties., PMID:23116517
Novel CD20 monoclonal antibodies for lymphoma therapy., PMID:23057966
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas., PMID:22271448
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies., PMID:22039078
Rituximab resistance., PMID:21658619
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma., PMID:21173095
Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development., PMID:21105187
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies., PMID:21090841
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells., PMID:20876805
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias., PMID:20628151
Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus., PMID:20534646
The future of CD20 monoclonal antibody therapy in B-cell malignancies., PMID:20367564
CD20-targeted therapy: the next generation of antibodies., PMID:20350667
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects., PMID:20214444
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides., PMID:20127947
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas., PMID:19710501
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia., PMID:19562616
[Novel B-cell directed strategies for the treatment of rheumatic diseases]., PMID:19513729
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results., PMID:19451441
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma., PMID:19372261
Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura., PMID:19330725
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma., PMID:19223402
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody., PMID:18941114
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics., PMID:18922911
For research use only. Not for human or drug use.
